Last reviewed · How we verify
Agriflu (TIV)
Agriflu is a trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus.
Agriflu is a trivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against three strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | Agriflu (TIV) |
|---|---|
| Also known as | Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived) |
| Sponsor | Novartis |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing three seasonal flu strains (typically two A strains and one B strain). When administered, it triggers the adaptive immune response, leading to production of neutralizing antibodies and cellular immunity against these specific viral strains, providing protection against infection or reducing disease severity if infection occurs.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia (muscle pain)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- Post-exposure Influenza Prophylaxis (PHASE3)
- Opioid, HIV and Immune System (PHASE4)
- Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
- Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge
- Influenza Human Challenge Model (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Agriflu (TIV) CI brief — competitive landscape report
- Agriflu (TIV) updates RSS · CI watch RSS
- Novartis portfolio CI